Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (WONDERS)

This study has been completed.
Information provided by (Responsible Party):
Octapharma Identifier:
First received: May 27, 2011
Last updated: May 19, 2014
Last verified: May 2014

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Condition Intervention Phase
Prevent Bleeding in Major Surgery
Biological: human VWF/FVIII concentrate
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures

Resource links provided by NLM:

Further study details as provided by Octapharma:

Primary Outcome Measures:
  • overall hemostatic efficacy (success or failure) of wilate, based on the intra-operative assessment of the surgeon and the post-operative assessment by the investigator using a 4-point ordinal efficacy scale. [ Time Frame: 30 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assessment of intra-operative hemostatic efficacy [ Time Frame: 30 Days ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: June 2011
Study Completion Date: April 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: human VWF/FVIII concentrate Biological: human VWF/FVIII concentrate
intravenous infusion. Dose based on subject's individual invivo-recovery


Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with congenital VWD (von Willebrand Disease)
  • Require therapy with a VWF (von Willebrand Factor) product to treat any major surgical procedure

Exclusion Criteria:

  • Known coagulation disorder other than VWD
  • Known history of, or suspected VWF or FVIII inhibitors
  • Subjects with hepatic liver disease
  • Known or suspected hypersensitivity or previous evidence of severe side effects to wilate or other VWF/FVIII concentrates
  • Pregnant women in the first 20 weeks of gestation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365546

United States, Indiana
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, United States, 46260
United States, North Carolina
UNC-CH Comprehensive Hemophilia Center
Chapel Hill, North Carolina, United States, 27599
United States, Wisconsin
Blood Center of Wisconsin
Milwaukee, Wisconsin, United States, 53201
SHAT Joan Pavel
Sofia, Bulgaria, 1233
Christian Medical College
Vellore, Tamil Nadu, India, 632004
Sahyadri Specialty Hospital
Pune, India, 411004
Azienda Ospedaliero Universitaria Careggi
Florence, Italy, 50133
Granda Ospedale Maggiore Policlinico
Milano, Italy, 20122
ULSS6 Vicenza Ematologia
Vicenza, Italy, 36100
Sultan Quaboos University Hospital
Muscat, Oman, PC123
Instytut Hematologii i Transfuzjologii
Warsaw, Poland, 0.-776
Fundeni Clinical Institute
Bucharest, Romania, 022328
Louis Turcanu Childrens Emergency Hospital
Timisoara, Romania, 300011
South Africa
Hemophilia Comprehensive Care Center
Johannesburg, South Africa, 2193
Ege University
Izmir, Turkey, 35100
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Octapharma Identifier: NCT01365546     History of Changes
Other Study ID Numbers: Wil-24
Study First Received: May 27, 2011
Last Updated: May 19, 2014
Health Authority: United States: Food and Drug Administration
India: Drugs Controller General of India
South Africa: Medicines Control Council
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: Ministry of Public Health
Turkey: Ministry of Health
Bulgaria: Ministry of Health

Additional relevant MeSH terms:
Von Willebrand Diseases
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Blood Platelet Disorders
Coagulation Protein Disorders
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders processed this record on March 03, 2015